Sugi Predict

Sugi Predict / Compounds / SCHEMBL288206

SCHEMBL288206

SCHEMBL288206

N[C@H](CC(=O)O)Cc1ccc(Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 1/20 0.64
▸ DPP4 P27487 1/20 0.54
▸ DPP7 Q9UHL4 1/20 0.54
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ CYP2C9 P11712 3/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ GABBR2 O75899 3/20 0.50
▸ GABBR1 Q9UBS5 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ ANPEP P15144 2/20 0.50
▸ ENPEP Q07075 2/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2033002 1.00 SLC6A4 (0.64) SLC6A4DPP4DPP7MEN1KMT2A
SCHEMBL2031957 1.00 SLC6A4 (0.64) SLC6A4DPP4DPP7MEN1KMT2A
SCHEMBL288276 0.83 SLC7A5 (0.61) ANPEPENPEPSLC6A2
SCHEMBL28064621 0.83 ANPEP (0.51) SLC6A4DPP4ANPEPENPEP
SCHEMBL27999577 0.83 ANPEP (0.51) SLC6A4DPP4ANPEPENPEP
SCHEMBL25229867 0.83 SLC7A5 (0.61) ANPEPENPEPSLC6A2
SCHEMBL28064620 0.83 ANPEP (0.51) SLC6A4DPP4ANPEPENPEP
SCHEMBL28064695 0.83 ANPEP (0.51) SLC6A4DPP4ANPEPENPEP
SCHEMBL288929 0.83 ANPEP (0.51) SLC6A4DPP4ANPEPENPEP
SCHEMBL123055 0.82 EPHX1 (0.64) DPP4ANPEPENPEPCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 — — US claimed
EP-2836485-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2018-01-10 — — EP claimed
EP-2499148-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2017-01-18 — — EP claimed
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2015-02-19 — — US claimed
EP-2836485-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS Polyphor Ag (CH) 2015-02-18 — — EP claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 — — EP claimed
WO-2013139697-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2013-09-26 — — WO claimed
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-10-25 — — US claimed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 — — CN disclosed
US-20110236429-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-09-29 — — US disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 — — US disclosed
WO-2010127704-A1 BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY POLYPHOR AG (CH) 2010-11-11 — — WO disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 — — EP disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 — — WO disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT SLC6A4 1543/4885DPP4 1357/4885DPP7 865/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 SLC6A4 308/4885DPP4 1271/4885DPP7 1768/4885
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds CTSE, CTSB, CTSS SLC6A4 3345/4885DPP4 1236/4885DPP7 1433/4885
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS KCNB1, KCNAB1, KCNMB1 SLC6A4 439/4885DPP4 2497/4885DPP7 2031/4885
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS CTSE, CTSB, CTSS SLC6A4 3345/4885DPP4 1236/4885DPP7 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.